TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 0.450nMAssay Description:Inhibition of human PAR4 expressed in HEK293 cells assessed as Ala-(L-4-F-Phe)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-induced inhibition of calcium mobiliza...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 0.530nMAssay Description:Antagonist activity at human PAR4 expressed in Ga15-HEK293 cells assessed as reduction in PAR4 AP AYPGKF-NH2-induced cytosolic calcium incubated for ...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 0.560nMAssay Description:Inhibition of human PAR4 expressed in HEK293 cells assessed as Ala-(L-4-F-Phe)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-induced inhibition of calcium mobiliza...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Antagonist activity at human PAR4 expressed in Ga15-HEK293 cells assessed as reduction in PAR4 AP AYPGKF-NH2-induced cytosolic calcium incubated for ...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 0.700nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 0.700nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 0.900nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of human PAR4 expressed in HEK293 cells assessed as Ala-(L-4-F-Phe)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-induced inhibition of calcium mobiliza...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Antagonist activity at human PAR4 expressed in Ga15-HEK293 cells assessed as reduction in PAR4 AP AYPGKF-NH2-induced cytosolic calcium incubated for ...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.20nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.30nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Inhibition of PD-1-Ig/His-PD-L1 (unknown origin) protein-protein interaction incubated with PD-L1 for 15 mins followed by addition of PD-1 for 15 min...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.40nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.5nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.5nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.5nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.5nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:Inhibition of Tag2-PD-1/Tag1-PD-L1 (unknown origin) protein-protein interaction incubated for 15 mins by HTRF assayMore data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.70nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.70nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.80nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 1.90nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at PAR4 in human platelet-rich plasma assessed as inhibition of gamma-thrombin-induced platelet aggregation preincubated for 5 mi...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.10nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.20nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.40nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.40nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.40nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.40nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetProteinase-activated receptor 4(Homo sapiens (Human))
China Pharmaceutical University
Curated by ChEMBL
China Pharmaceutical University
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of human PAR4 expressed in HEK293 cells assessed as Ala-(L-4-F-Phe)-Pro-Gly-Trp-Leu-Val-Lys-Asn-Gly-induced inhibition of calcium mobiliza...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.5nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.60nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.70nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.80nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.90nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair
TargetTyrosine-protein phosphatase non-receptor type 11(Homo sapiens (Human))
Betta Pharmaceuticals
US Patent
Betta Pharmaceuticals
US Patent
Affinity DataIC50: 2.90nMAssay Description:SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step re...More data for this Ligand-Target Pair